Teva Targets Amgen Over Kidney Drug

Law360, New York (May 22, 2009, 12:00 AM EDT) -- Teva Pharmaceutical Industries Ltd. has fired off a suit accusing Amgen Inc. of infringing its patent by making and selling Sensipar, a drug to treat kidney disease.

The Israeli generic-drug maker, which is seeking federal approval to launch a generic version of the kidney treatment, lodged the suit in the U.S. District Court for the Eastern District of Pennsylvania on May 20, claiming Amgen is violating the invention when it makes Sensipar.

Amgen, a biotech firm based in Thousand Oaks, Calif., holds a new drug application...
To view the full article, register now.